Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Panobinostat

EU orphan designation number: EU/3/12/1063   
Active ingredient: Panobinostat
Indication: Treatment of multiple myeloma
Sponsor: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Farydak on with the number EU/1/15/1023

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/11/2012 Orphan Designation EMA/OD/113/12 (2012)8196 of 08/11/2012